Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concer...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cell host & microbe Ročník 30; číslo 1; s. 97
Hlavní autoři:	Tauzin, Alexandra, Gong, Shang Yu, Beaudoin-Bussières, Guillaume, Vézina, Dani, Gasser, Romain, Nault, Lauriane, Marchitto, Lorie, Benlarbi, Mehdi, Chatterjee, Debashree, Nayrac, Manon, Laumaea, Annemarie, Prévost, Jérémie, Boutin, Marianne, Sannier, Gérémy, Nicolas, Alexandre, Bourassa, Catherine, Gendron-Lepage, Gabrielle, Medjahed, Halima, Goyette, Guillaume, Bo, Yuxia, Perreault, Josée, Gokool, Laurie, Morrisseau, Chantal, Arlotto, Pascale, Bazin, Renée, Dubé, Mathieu, De Serres, Gaston, Brousseau, Nicholas, Richard, Jonathan, Rovito, Roberta, Côté, Marceline, Tremblay, Cécile, Marchetti, Giulia C, Duerr, Ralf, Martel-Laferrière, Valérie, Kaufmann, Daniel E, Finzi, Andrés
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 12.01.2022
Témata:	Adult Aged Antibodies, Neutralizing - immunology Antibodies, Viral - immunology BNT162 Vaccine - immunology COVID-19 - immunology COVID-19 - virology COVID-19 Vaccines - immunology Female Humans Immunity, Humoral - immunology Male Middle Aged mRNA Vaccines - immunology SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - immunology Vaccination - methods Vaccines, Synthetic - immunology Young Adult COVID-19 delayed mRNA vaccine regimen humoral responses variants of interest SARS-CoV-2 Coronavirus variants of concern neutralization ADCC Spike glycoproteins
ISSN:	1934-6069, 1934-6069
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1934-6069 1934-6069
DOI:	10.1016/j.chom.2021.12.004